Genentech’s Vabysmo Slowly Chips Away at Competition in the Neovascular (Wet) AMD Market While Regeneron’s Eylea Holds its Ground (For Now), According to New Spherix Report
Newer ranibizumab entrants, Byooviz (Samsung/Biogen) and Susvimo (Genentech), struggle to make an impact EXTON, Pa., September 1, 2022 /PRNewswire/ – Since the FDA approval in January this year, ophthalmologists have been very optimistic about their intended use of Genentech’s Vabysmo (faricimab-svoa) for the treatment of neovascular (wet) age-related macular degeneration (nAMD). The latest quarterly report […]
Regeneron’s Eylea Could Lose 30% of its Patients to Roche’s Vabysmo Over the Next Year: Analyst Survey
Changes Afoot in US Age-Related Macular Degeneration Market as Prescribers Brace for the Launch of Biogen and Samsung Bioepis’ Byooviz, According to Spherix Global Insights
Physician-reported treatment patterns suggest that Byooviz could soon be competitive with Genentech’s Lucentis, but not likely to displace Regeneron’s Eylea EXTON, Pa., June 8, 2022 / PRNewswire/ — After several years of lackluster reception towards off-label biosimilar, Genentech’s Avastin (bevacizumab), ophthalmologists have finally seen the greenlight of a biosimilar that was studied and FDA approved […]
Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and Ophthalmology
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice and what baseline opinions will they be bringing as they move from a training environment into real world patient management EXTON, Pa., June 7, 2022 /PRNewswire/ — Fellows will be the next generation of practitioners. […]
Biogen, Samsung Bioepis Launch First US Biosimilar, a Copycat of Roche’s Lucentis, at 40% Discount
Despite the partners’ excitement, a recent survey by Piper Sandler and Spherix Global Insights found that in the presence of Regeneron’s market-leading anti-VEGF eye drug, Eylea, ophthalmologists are “largely ambivalent” with Byooviz and other VEGF copycats of Roche’s Avastin.
Roche’s Susvimo Has its Advantages, but Eye Doctors are Sticking with Eylea
Roche’s new eye drug delivery therapy Susvimo is becoming well known among eye doctors, but it has a major battle on its hands to shift market share away from the major blockbuster that is Regeneron and Bayer’s Eylea. This is according to a new report from Spherix analysts, based on conversations with 76 ophthalmologists in […]
Spherix Global Insights Announces Exhibition and Releases the Title of Their Abstract to be Presented at the 2022 ARVO Annual Meeting
Recent survey data reveals changes afoot in the neovascular (wet) age-related macular degeneration market EXTON, Pa., March 2, 2022 /PRNewswire/ — Spherix Global Insights, an independent market intelligence firm, recently collected feedback from 103 US ophthalmologists on the neovascular age-related macular degeneration (nAMD) treatment landscape. Insights from the RealTime Dynamix™ report revealed that market leader, […]
Roche’s Vabysmo to Offer ‘Fierce Competition’ to Regeneron’s Eylea, But a Long Market Battle Awaits: Spherix
Content Area
Ophthalmologists Welcome Genentech’s Vabysmo, Though Overthrowing Regeneron’s Eylea Will Be No Small Feat, Spherix Reports
Recent survey data reveals changes afoot in the neovascular (wet) age-related macular degeneration market EXTON, Pa., March 2, 2022 /PRNewswire/ — Spherix Global Insights, an independent market intelligence firm, recently collected feedback from 103 US ophthalmologists on the neovascular age-related macular degeneration (nAMD) treatment landscape. Insights from the RealTime Dynamix™ report revealed that market leader, […]
